Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Immune perturbation following SHIV infection is greater in newborn macaques than in infants
Mariya B. Shapiro, Tracy Ordonez, Shilpi Pandey, Eisa Mahyari, Kosiso Onwuzu, Jason Reed, Heather Sidener, Jeremy Smedley, Lois M. Colgin, Amanda Johnson, Anne D. Lewis, Benjamin Bimber, Jonah B. Sacha, Ann J. Hessell, Nancy L. Haigwood
Mariya B. Shapiro, Tracy Ordonez, Shilpi Pandey, Eisa Mahyari, Kosiso Onwuzu, Jason Reed, Heather Sidener, Jeremy Smedley, Lois M. Colgin, Amanda Johnson, Anne D. Lewis, Benjamin Bimber, Jonah B. Sacha, Ann J. Hessell, Nancy L. Haigwood
View: Text | PDF
Research Article AIDS/HIV Immunology

Immune perturbation following SHIV infection is greater in newborn macaques than in infants

  • Text
  • PDF
Abstract

Transmission of HIV-1 to newborns and infants remains high, with 130,000 new infections in 2022 in resource-limited settings. Half of HIV-infected newborns, if untreated, progress to disease and death within 2 years. While immunologic immaturity likely promotes pathogenesis and poor viral control, little is known about immune damage in newborns and infants. Here we examined pathologic, virologic, and immunologic outcomes in rhesus macaques exposed to pathogenic simian-human immunodeficiency virus (SHIV) at 1–2 weeks, defined as newborns, or at 4 months of age, considered infants. Kinetics of plasma viremia and lymph node seeding DNA were indistinguishable in newborns and infants, but levels of viral DNA in gut and lymphoid tissues 6–10 weeks after infection were significantly higher in newborns versus either infant or adult macaques. Two of 6 newborns with the highest viral seeding required euthanasia at 25 days. We observed age-dependent alterations in leukocyte subsets and gene expression. Compared with infants, newborns had stronger skewing of monocytes and CD8+ T cells toward differentiated subsets and little evidence of type I interferon responses by transcriptomic analyses. Thus, SHIV infection reveals distinct immunological alterations in newborn and infant macaques. These studies lay the groundwork for understanding how immune maturation affects pathogenesis in pediatric HIV-1 infection.

Authors

Mariya B. Shapiro, Tracy Ordonez, Shilpi Pandey, Eisa Mahyari, Kosiso Onwuzu, Jason Reed, Heather Sidener, Jeremy Smedley, Lois M. Colgin, Amanda Johnson, Anne D. Lewis, Benjamin Bimber, Jonah B. Sacha, Ann J. Hessell, Nancy L. Haigwood

×

Figure 4

Acute SHIV infection impairs humoral responses to HepB vaccine in newborns.

Options: View larger image (or click on image) Download as PowerPoint
Acute SHIV infection impairs humoral responses to HepB vaccine in newbor...
(A) Plasma IgG binding titers to hepatitis B (HepB) surface antigen recombinant protein (HBsAg) in newborns (top), infants (middle), and a comparison group of approximately age-matched infants without detectable SHIV viremia (bottom). These animals, termed aviremic infants, were exposed to SHIVSF162P3 on the same day as their first HepB vaccine dose, followed 30 hours later by a neutralizing antibody treatment that halted infection, resulting in undetectable viremia. Blue dotted lines at x = 0 and x = 6 denote the first and second HepB vaccine doses; newborns only received the first dose. Yellow shaded areas indicate time periods after SHIV exposure. (B) Kaplan-Meier analysis of the percentage of animals in each group with HBsAg antibodies. Log-rank test, P = 0.0115; n = 6 animals per group. (C) Comparison of HBsAg binding titers in group 2 infants and aviremic infants at either 14 weeks (top) or 24 weeks (bottom) after the first dose of HepB vaccine (unpaired t tests, 2-tailed P = 0.8225 and P = 0.8473 for weeks 14 and 24, respectively; n = 6 animals per group). Animal symbols are consistent throughout the manuscript. Data represent mean ± SEM. (D) Plasma IgG binding titers to HIV-SF162 Env gp140 glycoprotein in newborns (top) and infants (bottom). Black arrow indicates the only sample with neutralizing activity against SHIVSF162P3 (ID50 = 1,200). (E) Kaplan-Meier analysis of the percentage of animals that developed binding antibodies to SF162 gp140 by the indicated time points. Log-rank test, P = 0.8354, n = 6 animals per group.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts